Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study

Stephanie PepinSanofi Pasteur, Marcy-l'Étoile, FranceCorrespondence[email protected]

Henryk SzymanskiDepartment of Pediatrics, St. Hedvig of Silesia Hospital, Trzebnica, Poland

Ilya Angélica Rochín KobashiCentro de Investigación Clínica del Pacífico (CICPA), Acapulco, Guerrero, Mexico

Sandra Villagomez MartinezInstituto Nacional de Pediatria, Centro Pediátrico de Investigación Comunitario-Tlaltizapan, Tlaltizapan, Morelos, Mexico

José Francisco González ZamoraInstituto Nacional de Pediatria, Unidad de Apoyo a la Investigación Clinica – Planta Baja Insurgentes Sur #3700-C, Coyoacán, Mexico, D.F.

Jerzy BrzostekZespół Opieki Zdrowotnej, Poradnia Chorób Zakaźnych, Dębica, Poland

Li-Min HuangNational Taiwan University Hospital, Department of Pediatrics, Division of Infectious Diseases 7, Taipei, Taiwan, R.O.C

Cheng-Hsun ChiuDepartment of Pediatrics, Chang Gung Children's Hospital, Chang Gung University, Kweishan, Taoyuan, Taiwan, R.O.C.

Po-Yen ChenTaichung Veterans General Hospital, Taichung, Taiwan, R.O.C

Anitta AhonenVaccine Research Centre, University of Tampere Medical School, Tampere, Finland

Aino ForsténVaccine Research Centre, University of Tampere Medical School, Tampere, Finland

Ilkka SeppäVaccine Research Centre, University of Tampere Medical School, Tampere, Finland

René Farfán QuirozHospital Infantil de Tlaxcala, Calle 20 de Noviembre s/n, Carretera a San Damian Tlacocalpan, Km. 2.5 San Matías Tepetomatitlan, Municipio de Apetatitlan de Antonio Carvajal, Tlaxcala, Mexico

Tiina KorhonenVaccine Research Centre, University of Tampere Medical School, Tampere, Finland

Enrique RivasSanofi Pasteur, Coyoacan, Cd de Mexico, D.F.

Celine MonfredoSanofi Pasteur, Marcy-l'Étoile, France

Yanee HutagalungSanofi Pasteur, Singapore

Josemund MenezesSanofi Pasteur, Singapore

Timo VesikariVaccine Research Centre, University of Tampere Medical School, Tampere, Finland

show all

Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study

KHVI_A_1212143_Supplement.zip

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study

KHVI_A_1212143_Supplement.zip

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date